Guide to Authors

Welcome to the electronic manuscript submission website for Cancer Gene Therapy. The instructions below are structured so you can quickly and easily answer the following questions:

1. Is my manuscript suitable for Cancer Gene Therapy? (Scope + Editorial Note)
2. How do I format my manuscript for Cancer Gene Therapy? (Format of Papers)
3. How do I submit my manuscript to Cancer Gene Therapy? (Submission of Papers)

OTHER LINKS

• About the journal
• Format of papers
• Preparation of Original Articles
• House style
• Submission of papers
• Editorial policy
• Ethics and bioethics
• Peer review policy
• Corrections
• About npg online services

ABOUT THE JOURNAL

Scope

Topics Covered
RNAi approaches, drug resistance, hematopoietic gene transfer, homologous recombination, ribozyme technology, antisense technology, tumor immunotherapy and tumor suppressors,translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy (antisense, siRNA & ribozymes), apoptosis; mechanisms and therapies , vaccine development, immunology and immunotherapy, DNA synthesis and repair, etc.

Editors	R E Sobol, Sidney Kimmel Cancer Center, San Diego, California K J Scanlon, Keck Graduate Institute, Claremont, California
Frequency	12 issues a year
Abstracted in	Chemical Abstracts BIOSIS Science Citation ISI Alerting Services SciSearch The Biotechnology Citation Index Current Contents/Life Sciences Current Contents/Clinical Medicine Index Medicus/MEDLINE

Editorial Note

1. All named authors have agreed to its submission
2. It is not currently being considered for publication by another journal
3. If the paper is accepted it will not subsequently be published in the same or similar form in any language without the consent of publishers
4. Authors have obtained permission from their employers or institution to publish, if they have a contractual or moral obligation to do so.

Original Research Articles should include, as appropriate:

1. A clear statement of purpose;
2. A historical review when desirable;
3. A description of the procedures, methods, and subjects or materials used (previously published procedures require only references to the original);
4. A full report of the findings, including discussion and references to relevant findings of other researchers.

FORMAT OF PAPERS

Article Types Table

Article Type	Description
Original Article	These should follow the structure outlined below
Review	Updates on progress in the main field of Drug Resistance/ Sensitivity Gene Therapy, Tumor Suppressor and Anti-Oncogene Therapy, Cytokine/Tumor Immunotherapy, etc.
Short Communications	Shorter descriptions of important innovative developments will be considered for preliminary publication. These should consist of two pages of text, one figure or table and up to 10 references
Letters to the Editor	Brief comments on articles published in the journal or other information of interest to our readers

Preparation of Original Articles

Abstract and Keywords
The abstract should not exceed 200 words and three to six keywords should be included to aid web searches after publication.

References
Only papers directly related to the article should be cited. Exhaustive lists should be avoided. References should follow the Vancouver format. In the text they should appear as numbers starting at one and at the end of the paper they should be listed (double-spaced) in numerical order corresponding to the order of citation in the text. All authors should be quoted for papers with up to six authors; for papers with more than six authors, the first six only should be quoted, followed by et al. Abbreviations for titles of medical periodicals should conform to those used in the latest edition of Index Medicus. The first and last page numbers for each reference should be provided. Abstracts and letters must be identified as such. Papers in press and papers already submitted for publication may be included in the list of references but no citation is required for work that is not yet submitted for publication.

Journal article, up to six authors:
Rutanen J, Turunen A-M, Teittinen M, Rissanen TT, Heikura T, Koponen JK et al. Gene transfer using the mature form of VEGF-D reduces neointimal thickening through nitric oxide-dependent mechanism. Gene Ther 2005; 12: 980–987.

Journal article, e-pub ahead of print:
Couderc B, Pradines A, Rafii A, Golzio M, Deviers A, Allal C et al. In vivo restoration of RhoB expression leads to ovarian tumor regression. Cancer Gene Ther; e-pub ahead of print 14 March 2008; doi:10.1038/cgt.2008.12

Journal article, in press:
Wang R, Lin F, Wang X, Gao P, Dong K, Zou A-M et al. Silencing Livin gene expression to inhibit proliferation and enhance chemosensitivity in tumor cells. Cancer Gene Ther (in press).

Complete book:
Gordon MY, Barre AJ. Bone Marrow Disorder: the Biological Basis of Clinical Problems. Blackwell Scientific Publishers: Oxford, 1985.

Chapter in book:
Meyerowitz BE, Heinrich RI, Schag CC. A competency-based approach to coping with cancer. In: Burish TG, Bradley L (eds). Coping With Chronic Illness: Research and Applications, 2nd edn. Academic Press: New York, 1983, pp 137–158.

Abstract:
Feig SA, Lenarsky C, Moss T, Gallardo RL, Juneja HS, Gordon MY et al. Bone marrow transplantation for neuroblastoma. Exp Hematol 1985; 13(Suppl 2): 362 (abstract 102).

Correspondence
Kyritsis AP, Rao JS, Puduvalli VK. Radio-responsive TRAIL gene therapy for malignant gliomas [letter]. Cancer Gene Ther 2007; 14: 1002.

EndNote users should select the Cancer Gene Therapy output style for the correct reference style.

Personal communications must be allocated a number and included in the list of references in the usual way or simply referred to in the text; the authors may choose which method to use. In either case authors must obtain permission from the individual concerned to quote his/her unpublished work.

House Style

SUBMISSION OF PAPERS

Upon acceptance, authors must fill out and send back a payment form. This is mandatory and failure to send in the payment form along with the Licence to Publish form will result in the article being published as a standard paper behind access control. The licence to publish form has been amended to offer authors the choice of which licence to use on their paper and these choices are described below:

The first is the Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 Unported Licence and allows readers to download the article and share it with others as long as they mention the author and link back to the original article. The article cannot be changed in any way or used commercially.

The second is the Creative Commons Attribution Noncommercial Share Alike 3.0 Unported Licence and allows readers to alter, transform, or build upon the article and then distribute the resulting work under the same or similar license to this one. The work must be attributed back to the original author and commercial use is not permitted.

For further information please see the Cancer Gene Therapy Open FAQs and payment form.

Page charges
Manuscripts accepted for publication in CGT will incur a page charge of $107 per printed page for pages 1 to 6. Each additional page over 6 printed pages will incur a page charge of $214 per printed page. Payment details must be included on the form accompanying the proofs.

Colour charges

Further information
To find out who to contact for advertising, subscriptions, permissions, papers in production or publishing a supplement, please visit our publisher’s contacts page. Alternatively, you can write to: Cancer Gene Therapy, Nature Publishing Group, Academic Journals, 75 Varick Street, 9th Floor, New York, NY 10013 USA.

EDITORIAL POLICY

Statement of Ethics

Peer-review policy

Correction and retraction process

Non-Native Speakers of English
Researchers who are not native speakers of English who submit manuscripts to international journals sometimes receive negative comments from referees or editors about the English-language usage in their manuscripts, and these problems can contribute to a decision to reject a paper. To help reduce the possibility of such problems, we strongly encourage such authors to take at least one of the following steps:

• Have your manuscript reviewed for clarity by a colleague whose native language is English.
• Use one of the many English language editing services that are available, such as that offered by Nature Publishing Group Language Editing. An editor will improve the English to ensure that your meaning is clear and to identify problems that require your review.

Please note that the use of Nature Publishing Group Language Editing is at the author's own expense and in no way implies that the article will be selected for peer review or accepted by an NPG journal (or any other journal). The decisions that the editors of any NPG journal make based on the quality and suitability of a manuscript for that journal are entirely independent of whether that manuscript has been language-edited by Nature Publishing Group Language Editing.

Please press HOME to continue.